cefazolin + daptomycin

Cefazolin + daptomycin is a combination of two intravenous antibiotics used primarily for the treatment of severe infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Cefazolin is a first-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death. Daptomycin is a cyclic lipopeptide antibiotic that disrupts multiple aspects of bacterial cell membrane function; it binds to the membrane in a calcium-dependent manner, causing rapid depolarization and inhibition of protein, DNA, and RNA synthesis, resulting in bactericidal activity. This combination may be considered as salvage therapy for persistent or refractory MRSA bacteremia when standard treatments such as vancomycin have failed. The rationale for combining these agents includes potential synergistic effects against resistant organisms[1][7][10].